Geftinat 250 mg uses (Health & Beauty - Other Health Ads)

AUNetAds > Health & Beauty > Other Health Ads > Geftinat 250 mg uses

Item ID 1114470 in Category: Health & Beauty - Other Health Ads

Geftinat 250 mg uses


Free Online Advertising
Free Internet Web Site Advertising.


UK Free Classifieds
United Kingdom Free Ads Website.
100% Free Ad Posting.


Canada Free Ads
Popular Online Classifieds in Canada.
No Sign up, No Email Required to Post.

The Geftinat 250 mg tablet is an effective cure for the non-small lung cancer and it blocks the chemical action that actually supplies the cancer cell growth. In the market, one can get this medicine in a pack of thirty tablets in a bottle. It is required to take the effective precaution and one should nt go for the overdose of this medicine. The general dosage of this particular medicine is one tablet per day with a glass of water during the time of meals. If the medicine is taken in a overdose, there can be symptoms like rash and diarrhea. If the patient has Kidney or liver disease or is suffering from pulmonary fibrosis, do not use this medicine without consulting doctor.
The medicine is processed with the use of gefitinib and basically belongs to a class of anti-cancer medications known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Geftinat is widely consumed for the treatment of non-small cell lung cancer. This medicine effectively blocks the activity of chemicals, which increases the growth of cancer cells.

For Free Consulting
Phone No.- +91-120–2400370
Mob. : + 91-8130290915
WhatsApp: +91 8130290915
QQID:- 1927411523
Skype ID: praveen.sikri
Email ID: query@indiangenericmedicines.com


Related Link: Click here to visit item owner's website (0 hit)

Target State: All States
Target City : mumbai
Last Update : 04 December 2017
Number of Views: 21
Item  Owner  : Mary james
Contact Email:
Contact Phone: 8130290915

Friendly reminder: Click here to read some tips.
AUNetAds > Health & Beauty > Other Health Ads > Geftinat 250 mg uses
 © 2017 AUNetAds.com
2017-12-16 (0.079 sec)